SeekingAlpha
Discover why Immutep's Eftilagimod Alpha shows promise in NSCLC and HNSCC trials, but cautious investment is advised. Explore more details here.
Yahoo
First patient safely dosed at Calvary Mater Newcastle Hospital in Australia, marking a significant milestone for ImmutepGlobal Phase III with efti will enrol approximately 756 patients at more than 150 clinical sitesTrial results will inform potential marketing approval application in non-small cell lung cancer, one of the largest indications in oncology SYDNEY, AUSTRALIA, March 25, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immun
Yahoo
SYDNEY, AUSTRALIA, March 20, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces an upcoming poster presentation for the pivotal TACTI-004 Phase III trial. The poster will be presented at the European Lung Cancer Congress (ELCC) 2025, taking place in Paris, France, from 26-29 March 2025. The Trial in Progress poster includes an overview and study design of the
Yahoo
We recently published a list of 10 Best Australian Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Immutep Limited (NASDAQ:IMMP) stands against other best Australian stocks to buy according to billionaires. Australian Market Outlook 2025 In December 2024, Ausbil Investment Management Limited released its equity […]
Yahoo
We recently compiled a list of the 10 Best Long Term ASX Stocks to Buy Now. In this article, we are going to take a look at where Immutep Limited (NASDAQ:IMMP) stands against the other long term ASX stocks. Vanguard believes that Australia’s economy remains well-placed to recover gradually in 2025 after the broader economy witnessed […]
Yahoo
Media Release Marking Immutep’s transition to a Phase III biotech, the Company’s pivotal TACTI-004 trial in first-line non-small cell lung cancer (1L NSCLC) received first regulatory approvalMature data from INSIGHT-003 in 1L NSCLC demonstrates an excellent 32.9-month median overall survival (OS) and 81.0% 24-month OS rate, significantly outperforming historical controlsPromising new results in first line head & neck cancer with PD-L1 CPS <1 reported at ESMO IO 2024, with median OS not reached a
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
SANA | -<0.01% | $366.79M | -82.21% | 0.00% |
NINE | -0.01% | $49.12M | -54.15% | 0.00% |
HCSG | 0.01% | $751.04M | -17.51% | 0.00% |
RMD | -0.01% | $32.75B | +19.87% | 0.97% |
ASUR | -0.01% | $264.40M | +31.72% | 0.00% |
ABUS | 0.02% | $672.09M | +20.21% | 0.00% |
D | 0.02% | $47.91B | +15.63% | 4.73% |
PATH | -0.02% | $5.97B | -49.77% | 0.00% |
YEXT | -0.02% | $784.21M | +2.14% | 0.00% |
ORCL | 0.03% | $409.02B | +15.54% | 1.17% |
ODP | -0.03% | $442.21M | -71.19% | 0.00% |
MTDR | -0.03% | $6.54B | -23.72% | 2.17% |
DTM | 0.04% | $10.11B | +56.74% | 3.17% |
ESS | 0.04% | $19.76B | +29.35% | 3.33% |
JAZZ | 0.05% | $7.68B | +8.14% | 0.00% |
ENFN | 0.05% | $1.06B | +19.53% | 0.00% |
GSAT | 0.05% | $2.63B | +3.53% | 0.00% |
EXLS | -0.05% | $7.82B | +55.15% | 0.00% |
CPNG | -0.06% | $40.61B | +22.96% | 0.00% |
SWTX | 0.06% | $3.49B | +0.65% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
ELAN | 35.98% | $5.33B | -30.20% | 0.00% |
LEVI | 32.62% | $6.62B | -10.34% | 3.48% |
CIG.C | 25.62% | $2.35B | +14.03% | 0.00% |
CODX | 24.06% | $12.02M | -68.04% | 0.00% |
RXRX | 23.27% | $2.13B | -40.76% | 0.00% |
VSTM | 22.75% | $300.68M | -51.25% | 0.00% |
BAP | 21.30% | $15.40B | +15.76% | 4.90% |
WBA | 21.28% | $9.67B | -39.57% | 6.80% |
GCO | 20.90% | $244.50M | -20.09% | 0.00% |
PLAB | 20.83% | $1.30B | -27.97% | 0.00% |
LCID | 20.60% | $7.28B | -12.73% | 0.00% |
FSP | 20.59% | $187.46M | -15.42% | 2.29% |
EGAN | 20.37% | $136.43M | -22.77% | 0.00% |
ACRE | 20.36% | $244.66M | -37.88% | 20.98% |
JOUT | 20.33% | $260.81M | -43.26% | 5.62% |
NMAI | 19.56% | - | - | 14.10% |
NNOX | 19.43% | $287.24M | -54.79% | 0.00% |
SEVN | 19.33% | $192.54M | -0.23% | 11.02% |
OMAB | 18.85% | $3.36B | -3.77% | 5.85% |
NCMI | 18.81% | $571.15M | +6.95% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
VIXY | -18.45% | $195.31M | 0.85% |
TBLL | -13.80% | $2.13B | 0.08% |
PHDG | -13.29% | $114.98M | 0.39% |
TAIL | -12.58% | $87.65M | 0.59% |
MNA | -11.76% | $222.56M | 0.77% |
BTAL | -11.22% | $416.76M | 1.43% |
PWZ | -8.93% | $703.30M | 0.28% |
AGZD | -8.76% | $134.05M | 0.23% |
HIGH | -8.65% | $195.13M | 0.52% |
EQLS | -7.46% | $4.80M | 1% |
USO | -6.87% | $972.70M | 0.6% |
BNO | -6.48% | $99.25M | 1% |
OILK | -5.95% | $67.85M | 0.69% |
DBE | -5.92% | $55.52M | 0.77% |
FXE | -5.50% | $234.39M | 0.4% |
CANE | -5.18% | $11.28M | 0.29% |
BAR | -4.83% | $1.05B | 0.1749% |
OUNZ | -4.81% | $1.51B | 0.25% |
GLD | -4.68% | $93.86B | 0.4% |
DBO | -4.67% | $202.41M | 0.77% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
IBND | -0.02% | $184.11M | 0.5% |
BCD | 0.03% | $250.79M | 0.3% |
JPLD | -0.04% | $1.15B | 0.24% |
IHAK | -0.05% | $906.43M | 0.47% |
SHM | 0.06% | $3.42B | 0.2% |
CCOR | -0.07% | $64.12M | 1.18% |
IVOL | 0.09% | $476.36M | 1.02% |
TDTT | -0.09% | $2.38B | 0.18% |
MUNI | -0.11% | $1.83B | 0.35% |
LGLV | 0.14% | $943.89M | 0.12% |
BILZ | -0.16% | $734.41M | 0.14% |
COM | 0.20% | $242.21M | 0.72% |
STPZ | 0.23% | $427.83M | 0.2% |
IHI | -0.26% | $4.62B | 0.4% |
JMUB | -0.27% | $2.52B | 0.18% |
CGSM | -0.30% | $640.07M | 0.25% |
SUB | -0.33% | $8.76B | 0.07% |
MMIN | 0.33% | $473.48M | 0.3% |
TPMN | -0.36% | $33.32M | 0.65% |
IBMR | 0.36% | $222.54M | 0.18% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
ETHW | 41.41% | $178.76M | 0% |
EZET | 41.24% | $22.46M | 0% |
CETH | 41.17% | $10.49M | 0% |
ETHV | 41.13% | $87.97M | 0% |
ETHA | 41.11% | $2.27B | 0.25% |
QETH | 41.08% | $14.36M | 0.25% |
FETH | 40.95% | $762.75M | 0.25% |
ETH | 40.35% | $1.29B | 0% |
EFAA | 34.97% | $100.03M | 0% |
BTC | 32.77% | $3.28B | 0.15% |
QQA | 24.66% | $187.77M | 0% |
RSPA | 22.74% | $292.67M | 0% |
DBEU | 21.38% | $657.46M | 0.45% |
CPRJ | 20.81% | $48.38M | 0.69% |
FLTR | 20.74% | $2.41B | 0.14% |
LVHI | 20.13% | $2.34B | 0.4% |
GBIL | 19.84% | $6.30B | 0.12% |
DBEF | 19.78% | $7.78B | 0.35% |
HEFA | 19.58% | $7.70B | 0.35% |
ILF | 18.82% | $1.36B | 0.48% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
FIZZ | -23.26% | $3.90B | -9.84% | 0.00% |
LNN | -20.21% | $1.42B | +13.09% | 1.11% |
ATEX | -13.06% | $680.65M | +12.47% | 0.00% |
NHTC | -12.89% | $59.75M | -26.80% | 15.56% |
MEDP | -12.81% | $9.48B | -21.43% | 0.00% |
SUZ | -12.72% | $11.56B | -24.49% | 0.00% |
AJG | -12.51% | $87.99B | +40.23% | 0.71% |
BLCO | -11.53% | $5.06B | -12.98% | 0.00% |
LH | -11.35% | $19.78B | +11.37% | 1.24% |
SAVA | -11.30% | $67.15M | -93.25% | 0.00% |
GAN | -10.95% | $81.06M | +31.11% | 0.00% |
HUSA | -10.86% | $11.76M | -47.55% | 0.00% |
LDOS | -10.54% | $18.33B | +10.80% | 1.13% |
VRSK | -10.24% | $42.04B | +29.74% | 0.53% |
MUSA | -10.23% | $9.51B | +14.23% | 0.38% |
INFA | -10.12% | $5.37B | -49.82% | 0.00% |
UUU | -9.93% | $4.14M | +11.18% | 0.00% |
BAH | -9.80% | $14.29B | -23.63% | 1.87% |
IIIV | -9.78% | $588.52M | +12.39% | 0.00% |
TTEK | -9.63% | $8.26B | -19.20% | 2.32% |
Current Value
$1.631 Year Return
Current Value
$1.631 Year Return